The shares seem to be attractively priced at the moment and the companies appear to be financially sound. However, I'm not that familiar with the sector yet.
Neurocrine Biosciences (NASDAQ:NBIX) said the FDA has accepted its two new drug applications for priority review for its drug crinecerfont in the treatment of pediatric and adult patients with congenital adrenal hyperplasia, a rare endocrine disorder.
